Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Elizabeth A. Garofalo, a director at Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), recently sold 4,919 shares of the company’s common stock. The shares were sold at a price of $18.23 each, totaling approximately $89,673. The sale comes as the stock has declined nearly 9% over the past week, though InvestingPro analysis suggests the stock may be undervalued at current levels. Following this transaction, Garofalo holds 17,595 shares in the company. The sale was disclosed in a filing with the Securities and Exchange Commission, providing investors with insight into recent insider trading activities. Acadia Pharmaceuticals, based in San Diego, specializes in pharmaceutical preparations. The company maintains strong financial health with more cash than debt on its balance sheet and has demonstrated profitability over the last twelve months with a healthy gross margin of nearly 60%. Additional financial metrics and insights are available through InvestingPro’s comprehensive research report.
In other recent news, Acadia Pharmaceuticals has reported a strong financial performance for the fourth quarter of 2024, with revenue increasing by 12% year-over-year to $259.6 million. The company’s total revenue for the year reached $957.8 million, marking a 32% rise from the previous year, driven significantly by the 97% surge in DAYBUE sales. Looking ahead, Acadia projects 2025 revenue to be between $1.03 billion and $1.095 billion, with expectations for DAYBUE sales to reach between $380 million and $450 million. TD Cowen maintained a Buy rating for Acadia, with a price target of $35, citing the company’s fourth-quarter earnings that exceeded expectations and optimistic revenue guidance for FY25. Meanwhile, Citizens JMP adjusted Acadia’s price target to $37 from $39, retaining a Market Outperform rating, noting the stabilization of DAYBUE and the potential for robust growth in the latter half of 2025.
Acadia is also advancing its clinical pipeline, planning a Phase 2 trial for ’204 in Lewy Body Dementia in the third quarter of 2025, and anticipates releasing topline results from a Phase 3 trial for ’101 in Prader-Willi Syndrome in the first half of 2026. In other developments, the DAFFODIL study, published in the journal Med, supports the safety and tolerability of DAYBUE for treating Rett syndrome in children aged two to four. The study showed that DAYBUE had a similar safety profile in this age group as in older individuals, which contributed to the FDA’s approval for patients two years and older.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.